Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
AChE Inhibitor
Buxbodine B is an acetylcholinesterase (AChE) inhibitor with an IC50 of 50 μM. It demonstrates significant potential in the study of neurodegenerative diseases, particularly Alzheimer's disease, by modulating cholinergic transmission. Its inhibitory action on AChE facilitates the exploration of therapeutic strategies aimed at enhancing cognitive function and memory retention in affected populations. -
AChE Inhibitor
Arisugacin D is an acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 3.5 μM. This compound is notable for its potential to enhance synaptic acetylcholine levels, making it useful in studies related to neurodegenerative diseases such as Alzheimer's. The inhibition of AChE facilitates the investigation of cholinergic signaling pathways and the development of therapeutic strategies targeting cognitive decline. -
AChE1 Inhibitor
AL284 is a potent inhibitor of Anopheles gambiae acetylcholinesterase 1 (AgAChE1), targeting key residues Tyr489Ag and Trp441Ag within the enzyme structure. This compound demonstrates significant biological activity in disrupting neurotransmitter breakdown, which is critical for the survival of disease-transmitting mosquitoes. AL284 is valuable for research applications focused on controlling mosquito populations and studying vector-borne diseases. -
Cholinesterase Inhibitor
Neostigmine hydroxide is a potent cholinesterase inhibitor that enhances acetylcholine levels at neuromuscular junctions. This compound is primarily utilized in research related to myasthenia gravis and other neuromuscular disorders, aiding in the exploration of muscular function and neuropharmacology. Its ability to counteract muscle weakness makes it a valuable tool for studying therapeutic interventions in cholinergic signaling. -
AChE Inhibitor
Coroxon, an AChE inhibitor, is an oxidative metabolite of the organophosphate insecticide Coumaphos. This compound exhibits significant insecticidal and acaricidal activity, making it valuable for pest control research. Additionally, Coroxon can be hydrolyzed by phosphotriesterases from microorganisms such as Nocardia asteroides, resulting in the production of the fluorescent compound Chlorferon, which can be utilized in biochemical assays and studies related to enzyme activity. -
AChE Inhibitor
Salvianolic acid H is a potent inhibitor of acetylcholinesterase (AChE), serving to enhance cholinergic neurotransmission. Its primary biological activity includes the potential modulation of neurodegenerative processes associated with cognitive decline. This compound is valuable for research applications aimed at understanding Alzheimer's disease and other conditions linked to cholinergic deficits. -
hAChE Inhibitor
7-Methoxytacrine is a potent inhibitor of human acetylcholinesterase (hAChE) with an IC50 value of 10 μM. This compound is utilized in research related to Alzheimer's disease, highlighting its potential role in modulating neurotransmitter levels and improving cognitive function. Its mechanism of action makes it a valuable tool for investigating therapeutic strategies in neurodegenerative disorders. -
ChE Inhibitor
Lycodine is a lycopodium alkaloid that acts as a cholinesterase inhibitor. It demonstrates significant anticholinesterase activity, making it a valuable tool for research into neurological disorders and cognitive function. Its potential applications extend to studying mechanisms of acetylcholine modulation and developing therapeutic approaches for conditions such as Alzheimer’s disease. -
AChE Inhibitor
Graphislactone A is an acetylcholinesterase (AChE) inhibitor, which demonstrates significant potential in the investigation of neurodegenerative diseases. With an IC50 value of 27 μM, it effectively inhibits AChE activity, contributing to enhanced cholinergic signaling. Additionally, Graphislactone A exhibits antioxidant properties, making it a valuable compound for research focused on oxidative stress-related disorders. -
Cholinesterase (ChE) Inhibitor
Echinenone acts as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 16.29 μg/mL. This compound demonstrates anti-Aβ(25-35) activity and has been shown to decrease malondialdehyde (MDA) levels while enhancing the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px). These properties indicate its potential use in research focused on neuroprotection and alleviating oxidative stress-related damage. -
AChE Inhibitor
Isodimethoate is an acetylcholinesterase (AChE) inhibitor that demonstrates potent anticholinesterase activity. As a thermal decomposition product of Dimethoate, it effectively inhibits AChE in human red blood cells, making it valuable for studying cholinergic signaling and related neurochemical pathways. This compound is frequently utilized in research focused on neurotoxicology and the effects of organophosphates on enzymatic activity. -
AChE Inhibitor
Galactamine is an acetylcholinesterase (AChE) inhibitor that plays a crucial role in modulating neurotransmitter levels by preventing the breakdown of acetylcholine. This compound is primarily utilized in research investigating Alzheimer's disease and other neurodegenerative disorders, where it helps to elucidate the mechanisms underlying cognitive decline and potential therapeutic strategies. Galactamine's ability to enhance cholinergic signaling makes it a valuable tool in the study of efficacy and safety in neuropharmacology. -
hBuChE Inhibitor
Deoxynojirimycin tetrabenzyl ether is an inhibitor of human butyrylcholinesterase (hBuChE), with an IC50 value of 2.0 μM. This compound is utilized in research focused on neurological disorders and cholinergic system regulation, making it valuable for studies involving enzyme inhibition and potential therapeutic applications in cognitive decline. -
AChE Inhibitor
Arisugacin C is an acetylcholinesterase (AChE) inhibitor exhibiting an IC50 of 2.5 μM, demonstrating its potent activity in modulating cholinergic neurotransmission. This compound is valuable for research into neurodegenerative diseases, including Alzheimer’s disease, where AChE inhibition may alleviate cognitive decline. Its selectivity and efficacy make it a useful tool in studying the mechanisms of cholinergic signaling and developing potential therapeutic strategies. -
Monoamine Oxidase Inhibitor
4-Chlorochalcone is a selective monoamine oxidase inhibitor, demonstrating an IC50 of 0.082 μM against hMAO-B and 9.95 μM against hMAO-A. This compound also shows inhibitory activity towards acetylcholinesterase, with an IC50 of 2.79 μM. As a chalcone derivative, 4-Chlorochalcone is valuable for research focused on neurodegenerative diseases and the modulation of neurotransmitter levels. -
Cholinesterase (ChE) Inhibitor
AChE-IN-83 is a potent acetylcholinesterase (AChE) inhibitor targeting cholinesterases in various biological systems. This compound effectively inhibits the growth and behavior of Aphelenchoides oryzae, a nematode pathogen in rice, demonstrating an LC50 value of 19.0 μg/mL over 48 hours. AChE-IN-83 disrupts the nematode cuticle, promoting the accumulation of reactive oxygen species, lipofuscin, and lipids, thereby offering applications in nematode management and enhancing rice seed health. -
Cholinesterase Inhibitor
Mobam is a cholinesterase inhibitor with significant efficacy against Anoplura Pediculidae. This compound effectively reduces cholinesterase (ChE) levels in plasma, erythrocytes, and brain tissue of rat models, leading to suppressed avoidance behavior. Mobam is primarily utilized in toxicological research and studies focused on neurological effects and insecticidal applications. -
Cholinesterase (ChE) Inhibitor
SZ1676 is a cholinesterase (ChE) inhibitor that functions primarily by blocking the enzymatic activity of acetylcholinesterase. This compound demonstrates significant potential in studying neuromuscular transmission and related disorders. Its biological activity may support research in pharmacology and toxicology, particularly concerning neuromuscular blocking agents and their therapeutic implications. -
Glucosylceramide Synthase Inhibitor
Glucosylceramide synthase-IN-6 is a selective inhibitor of glucosylceramide synthase (GCS), targeting the enzymatic pathway involved in the synthesis of glucosylceramide. This compound is valuable for investigating the role of GCS in various diseases, particularly lysosomal storage disorders. Its application in research facilitates a better understanding of GCS activity and its implications in cellular metabolism and pathology. -
Glucosylceramide Synthase Inhibitor
Glucosylceramide synthase-IN-5 is a potent inhibitor of glucosylceramide synthase (GCS). This compound is instrumental in the exploration of diseases and disorders linked to GCS activity, particularly lysosomal storage disorders. Its ability to modulate GCS activity makes it a valuable tool in biochemical research aimed at understanding sphingolipid metabolism and related pathologies. -
Glucosylceramide Synthase Inhibitor
Lucerastat is a potent inhibitor of glucosylceramide synthase (GCS), specifically in its galactose form derived from Miglustat. This compound exhibits significant biological activity in modulating glycosphingolipid metabolism and has potential applications in the investigation of Fabry disease. Researchers may employ Lucerastat to explore therapeutic avenues and understand the pathophysiology associated with GCS-related disorders. -
GCS/GBA2 Inhibitor
Sinbaglustat is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). This N-alkyl iminosugar is orally bioavailable and capable of penetrating the blood-brain barrier, making it a valuable tool for investigating central neurodegenerative disorders linked to lysosomal dysfunction. Its unique properties facilitate research into potential therapeutic strategies for conditions such as Gaucher disease and other lysosomal storage disorders. -
Glucosylceramide Synthase Inhibitor
Ibiglustat (L-Malic acid) is a potent inhibitor of glucosylceramide synthase (GCS), demonstrating oral bioavailability and the ability to penetrate the blood-brain barrier. This compound is instrumental for research into various lysosomal storage disorders, including Gaucher disease type 3, Parkinson's disease linked to GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease. Its selective inhibition of GCS makes it a valuable tool for studying the biochemical pathways associated with these conditions. -
GCS Inhibitor
TP-060 is a glucosylceramide synthase (GCS) inhibitor, exhibiting potent inhibitory activity with IC50 values of 31 nM for human GCS and 51 nM for mouse GCS. This compound is orally active and capable of penetrating the blood-brain barrier, making it a valuable tool for investigating GCS-related pathways. TP-060 is particularly relevant for research into Gaucher's disease and other conditions associated with GCS dysregulation. -
GCS Inhibitor
D-threo-PDMP hydrochloride is a potent inhibitor of glucoceramide synthase (GCS), effectively reducing glycosphingolipids such as GM3 and GD3 on the cell surface. This compound impairs glycosylation processes, leading to reduced axonal growth and branching, as well as decreased adhesion of B16 melanoma cells, effectively mimicking the effects of hyperglycemia and TGF-β1. Additionally, D-threo-PDMP hydrochloride protects hepatocytes from TNF-α-induced apoptosis by inhibiting GD3 synthesis. This reagent is valuable for research into diseases associated with glycosphingolipid metabolism. -
Glucosylceramide Synthase Inhibitor
Ibiglustat succinate is a potent glucosylceramide synthase (GCS) inhibitor with oral bioavailability and the ability to penetrate the blood-brain barrier. This compound is primarily used in research focused on Gaucher disease type 3, Parkinson's disease linked to GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease. Its inhibitory action on GCS has potential implications for understanding and treating these neurodegenerative and lysosomal storage disorders. -
GCS Inhibitor
Glucosylceramide synthase-IN-2 is a potent, orally bioavailable inhibitor of glucosylceramide synthase (GCS), demonstrating IC50 values of 15 nM for human GCS and 190 nM for mouse GCS. This compound functions as a noncompetitive inhibitor in the presence of C8-ceramide and UDP-glucose. Glucosylceramide synthase-IN-2 is particularly useful for research into Gaucher's disease, offering valuable insights into the modulation of glycosphingolipid metabolism. -
GlcCer Synthase Inhibitor
D-threo-PPMP hydrochloride is a potent inhibitor of glucosylceramide (GlcCer) synthase, effectively disrupting the synthesis of glucosylceramide. This compound has been shown to block karyokinesis and reduce cyst production, making it a valuable tool for studying lipid metabolism and related pathophysiological conditions. Its application extends to research on lysosomal storage disorders and other diseases associated with glycolipid accumulation. -
GCS Inhibitor
Glucosylceramide synthase-IN-3 is a potent inhibitor of glucosylceramide synthase (GCS), demonstrating an IC50 of 16 nM for human GCS. This compound is brain-penetrant and orally active, making it suitable for in vivo studies. Glucosylceramide synthase-IN-3 is primarily used in research focused on Gaucher's disease and related glycosphingolipid metabolism disorders. -
GlcCer Synthase Inhibitor
D-threo-PPMP is a potent inhibitor of glucosylceramide (GlcCer) synthase, a critical enzyme in sphingolipid metabolism. Inhibition of GlcCer synthase by D-threo-PPMP has been shown to block karyokinesis and decrease cyst production, making it valuable for research into lysosomal storage disorders and related pathologies. This compound is essential for studies aimed at elucidating the role of GlcCer in cellular processes and disease mechanisms. -
Glucosylceramide Synthase Inhibitor
Ibiglustat hydrochloride is a potent glucosylceramide synthase (GCS) inhibitor that effectively penetrates the blood-brain barrier. This compound is primarily used in research related to Gaucher disease type 3, Parkinson's disease linked to GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease. Its mechanism of action contributes to the modulation of glucocerebroside metabolism, offering a valuable tool for studies focused on lysosomal storage disorders and related neurodegenerative conditions. -
Glucosylceramide Synthase Inhibitor
(−)-L-threo-PDMP hydrochloride is a potent inhibitor of glucosylceramide synthase (GCS). This compound has been shown to promote the proliferation of cultured aortic smooth muscle cells and elevate levels of lactosylceramide (LacCer) in B16 melanoma cells. Its unique activity profile makes it a valuable tool for research applications related to glycosphingolipid metabolism and cellular signaling pathways. -
GCS Inhibitor
EXEL-0346 is a potent glucosylceramide synthase (GCS) inhibitor, demonstrating an IC50 value of 2 nM. This compound enhances insulin signaling through an increase in pAkt levels while effectively decreasing the concentrations of glucosylceramide, lactosylceramide, and GM3. EXEL-0346 shows promise in addressing metabolic disorders, particularly obesity and diabetes, making it a valuable tool for research in these areas. -
GCS Inhibitor
Glucosylceramide synthase-IN-4 is a potent inhibitor of glucosylceramide synthase (GCS), exhibiting an IC50 value of 6.8 nM. This compound demonstrates favorable pharmacokinetic properties and stability in human hepatocytes, making it suitable for in vitro studies. Additionally, Glucosylceramide synthase-IN-4 exhibits effective central nervous system (CNS) penetration and maintains acceptable selectivity for PXR, facilitating research into GCS-related pathways and potential therapeutic applications in metabolic disorders. -
FUT8 Inhibitor
FUT8-IN-1 is a potent inhibitor of α-1,6-fucosyltransferase (FUT8), exhibiting a KD of 49 nM and an IC50 of approximately 50 µM. This compound generates a highly reactive naphthoquinone imine intermediate upon interaction with FUT8, effectively inhibiting its enzymatic activity. FUT8-IN-1 is valuable for investigating the role of FUT8 in glycosylation processes and its implications in various biological research applications. -
Monoamine Oxidase Inhibitor
MAO-B-IN-2 is a selective and competitive inhibitor of monoamine oxidase B (MAO-B) with an IC50 value of 0.51 μM, and it also inhibits butyrylcholinesterase (BChE) with an IC50 of 7.00 μM. This compound plays a significant role in studying neurodegenerative disorders by modulating monoamine metabolism, making it valuable for research into conditions such as Parkinson's disease and Alzheimer's disease. Its specificity for MAO-B makes it an important tool for exploring therapeutic pathways involving neurotransmitter regulation. -
O-GlcNAcase Inhibitor
O-GlcNAcase-IN-5 is a selective inhibitor of O-GlcNAcase, a key enzyme involved in the removal of O-GlcNAc modifications from proteins. By inhibiting this enzyme, O-GlcNAcase-IN-5 effectively prevents the deacetylation of tau protein, thereby reducing its excessive phosphorylation. This compound is particularly relevant for research in Alzheimer's disease and other neurodegenerative conditions where tau protein modification plays a critical role. -
OGT Inhibitor
OGT-IN-1 is a selective inhibitor of O-GlcNAc transferase (OGT), with IC50 values of 27 μM for soluble OGT (sOGT) and 10 μM for nuclear OGT (ncOGT). This compound plays a crucial role in regulating protein O-GlcNAcylation, thereby influencing various cellular processes such as signal transduction and gene expression. OGT-IN-1 is valuable for research applications focused on studying OGT-related metabolic disorders, cancer biology, and neurodegenerative diseases. -
OGT Inhibitor
PG 34 is a selective inhibitor of O-GlcNAc transferase (OGT), exhibiting an IC50 value of 68 μM. This compound targets the OGT enzyme, playing a crucial role in the regulation of O-GlcNAcylation. PG 34 is primarily applied in studies of cellular signaling, metabolic processes, and glycosylation-related research, offering insights into the role of OGT in various biological contexts. -
OGT Inhibitor
OGT-IN-4 is a potent inhibitor of O-GlcNAc transferase (OGT), displaying a dissociation constant (Kd) of 8 nM. This compound is valuable for investigating the role of OGT in various biological processes and diseases, including metabolic disorders and cancer. Its specificity makes OGT-IN-4 a useful tool for researchers studying O-GlcNAcylation and its impact on cellular signaling pathways. -
OGT Inhibitor
BZX2 is an irreversible covalent inhibitor of O-GlcNAc transferase (OGT), demonstrating an IC50 of less than 10 µM. This compound is cell-permeable, allowing for effective intracellular delivery, though it may exhibit multiple off-target effects. BZX2 is primarily utilized in research applications focused on OGT-related signaling pathways and O-GlcNAcylation processes in various biological contexts. -
TTBK1 Inhibitor
TTBK1-IN-1 is a selective inhibitor of tau tubulin kinase 1 (TTBK1), exhibiting an impressive IC50 of 2.7 nM. This compound demonstrates significant potential for the investigation of Alzheimer's disease and associated tauopathies. Additionally, TTBK1-IN-1 features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it a valuable tool for click chemistry applications in biological research. -
TTBK1 Inhibitor
TTBK1-IN-2 is a selective inhibitor of Tau-Tubulin kinase 1 (TTBK1), exhibiting IC50 values of 0.24 µM and 4.22 µM. This compound demonstrates significant brain penetration in vivo and effectively reduces TDP-43 phosphorylation in both cell culture models and the spinal cord of transgenic TDP-43 mice. TTBK1-IN-2 is valuable for research focused on neurodegenerative diseases, particularly those associated with TDP-43 pathology. -
Tau and α-syn Inhibitor
MG-2119 is a potent inhibitor of tau and α-synuclein aggregation, primarily acting on the monomeric forms of these proteins. This compound demonstrates significant potential in the study of neurological disorders, making it a valuable tool for researchers investigating the pathophysiology of tauopathies and synucleinopathies. Its inhibitory effects on protein aggregation could provide insights into therapeutic strategies for related neurodegenerative diseases. -
Tau Aggregation Inhibitor
BSc3094 acts as a Tau aggregation inhibitor, targeting the pathological accumulation of tau protein implicated in neurodegenerative diseases. This compound has shown potential in research focused on Alzheimer's disease, making it a valuable tool for studying tau-related mechanisms and therapeutic interventions for neurodegeneration. -
Tau Protein Inhibitor
NQTrp is a potent inhibitor of tau protein aggregation, functioning primarily through its interaction with amyloidogenic structures. This naphthoquinone-tryptophan hybrid exhibits significant anti-amyloidogenic properties, effectively inhibiting the in vitro aggregation of hexapeptide 41GCWMLY46, located in the N-terminus of γD-crystallin, as well as the full-length γD-crystallin. NQTrp is a valuable reagent for research applications focusing on neurodegenerative disorders, particularly those associated with tau pathology. -
Tau Aggregation Inhibitor
TAU-IN-4 is a potent inhibitor of tau aggregation, demonstrating a KD of 1.58 μM. This compound is primarily utilized in research focused on Alzheimer's disease, where it aids in the exploration of tau-related pathophysiological mechanisms. Its capability to inhibit tau aggregation makes it a valuable tool for studying neurodegenerative processes and potential therapeutic interventions. -
DYRK1A Inhibitor
ZJCK-6-46 is a potent DYRK1A inhibitor, demonstrating an IC50 of 0.68 nM. This compound exhibits high blood-brain barrier permeability, making it suitable for central nervous system applications. ZJCK-6-46 effectively reduces tau phosphorylation, contributing to the amelioration of cognitive dysfunction by decreasing phosphorylated tau levels and mitigating neuronal loss in vivo. Its biological activity positions it as a valuable tool for researching neurodegenerative diseases. -
Tau Protein Aggregation Inhibitor
Tau protein aggregation-IN-1 is an inhibitor of Tau protein aggregation. It has demonstrated significant potential in the study of neurodegenerative disorders associated with protein misfolding, including Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease, and prion-induced spongiform encephalopathies. This compound is essential for researchers investigating the mechanisms of Tau pathology and the development of therapeutic strategies targeting aggregated proteins. -
TTBK1/2 Inhibitor
TTBK1/2-IN-3 is a selective inhibitor of tau tubulin kinase 1 (TTBK1) and TTBK2, demonstrating IC50 values of 579 nM and 258 nM, respectively. This compound inhibits TDP-43 phosphorylation, thereby influencing protein aggregation pathways associated with neurodegenerative diseases. Additionally, TTBK1/2-IN-3 has been shown to reduce the expression of primary cilia on the surface of induced pluripotent stem cells (iPSCs), making it a valuable tool for research into cellular signaling and neurodegeneration.
